Viveve Medical Inc (NASDAQ: VIVE) Stock Coverage Initiated at Ladenburg Thalmann

Analysts at Ladenburg Thalmann initiated coverage on Viveve Medical Inc (NASDAQ: VIVE) stock, starting the company at Buy.Ladenburg Thalmann currently has a rating of Buy on the stock. The one-year price target of $12.76 is higher than the opening price of $7.35, that has caused a fair amount of other analysts to comment on the stock in recent days. Looking back over the last year, Viveve Medical Inc stock has a high of $10.50. After beginning or initiating coverage, analysts and brokerage firms will subsequently issue periodic updates. Price changes targets are not unusual.

U.S. stocks on Monday closed mostly flat, after trading firmly higher, in a volatile session ahead of the start of a pair of closely watched central-bank policy meetings.

The Dow Jones Industrial Average DJIA, -0.02% closed down 3.63 points at 18,120.17.

The blue-chip index had been up by as much as 131 points earlier and traded within a 162-point range.

The S&P 500 SPX, +0.00% slipped 0.04 points to close at 2,139.12, after trading within an 18-point range

Meanwhile, the Nasdaq Composite Index COMP, -0.18% declined 9.54 points, or 0.2%, to close at 5,235.03.

Earlier, the index had been up by as many as 37 points and traded with a 58-point range

Yesterday Viveve Medical Inc (NASDAQ: VIVE) shares last traded at $7.28, a spike of $0.28 over the previous closing price. Opening at $7.35, they ranged from $7.20 and $7.60 throughout the day.

Viveve Medical Inc (NASDAQ: VIVE) currently has a market cap of 77.21M.

28,520 shares crossed the trading desk yesterday, 107 percent below the norm, out of a total float 3,758,000. Swing traders often use swings in trading volume to determine substantial volume aggregation or distribution by institutional investors, so trading volume is likely to increase in the next few days.

While an increase in trading for one day will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is crucial.

Institutional sponsorship commonly refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these retain substantial teams of analysts researching thousands of stocks. So watching their interests is a good way to ensure you are buying the right stocks.

By tracking the activity of these professional investors and how they influence moving averages,it allows for traders to make more useful choices on trades.

With that in mind, Viveve Medical Inc (NASDAQ: VIVE) now has a 50-day MA of $7.58 and 200-day MA of $6.60. It has traded in a 52-week range between $4.02 – 10.50 and today’s last price is 0.31% lower than the 52 week high of $10.50.

Earnings growth is a critical factor to consider when buying stocks and investors identify companies that have grown their earnings at least 25% or more over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.